青龙衣胶囊在荷瘤小鼠体内抗肿瘤活性的研究  

Antitumor Activity of Qinglongyi Capsules in Vivo

作　　者：段玉敏[1] 张洪娟[1] 张志华[1] 王伟明[1] 

机构地区：[1]黑龙江省中医研究院,哈尔滨150036

出　　处：《中国实验方剂学杂志》2010年第9期125-127,共3页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：国家重大新药创制项目(2009ZX09102-138)

摘　　要：目的:研究青龙衣胶囊的抗肿瘤活性及对S 180荷瘤小鼠血清中SOD和MDA的影响。方法:采用人胃腺癌BGC-823,S 180肉瘤和肝癌H 22腹水瘤,分别以环磷酰胺为阳性对照组、生理盐水为阴性对照组,将青龙衣药物以高、中、低3个剂量对实验裸鼠、小鼠组ig给药。结果:青龙衣胶囊明显抑制人胃腺癌BGC-823荷瘤裸鼠瘤体的增长,监测结果显示对给药后期抑瘤作用增强,抑瘤率可达到68.1%(P<0.01);能抑制肉瘤S 180荷瘤小鼠瘤体的增长,抑瘤率达到61.2%(P<0.01),具有较强的抗氧化能力,显著提高SOD水平(P<0.05),降低MDA水平(P<0.05);能明显提高肝腹水小鼠的生存质量,延长肝腹水小鼠的带瘤生存时间,生命延长率达到86.6%(P<0.01)。结论:青龙衣胶囊具有明显的体内抗肿瘤活性。Objective：Study on antitumor activity of Qilongyi Capsules,and its influence to SOD and MDA in serum of tumor-bearing mice.Method：Used models of human gastric cancer BGC-823,tumors S180,liver cancer H22 ascites tumors.And used the methods of Qilongyi Capsules which were divided into three groups,hig,middle and low.Result：The Qinglongyi Capsules had remarkable affects at suppressing tumor,its inhibition rate on the tumors over 68.1%（P 0.01） to tumor-bearing nude mice and over 61.2%（P 0.01） to tumor-bearing mice,can significantly increase SOD levels（P 0.05） and lower MDA level（P 0.05）,and the life span was increased to 86.6%（P 0.01） for mouse with H 22and solid tumors.Conclusions：Through the experiments we can prove that Qilongyi Capsules has remarkable antitumor activity.

关 键 词：青龙衣胶囊 胃腺癌BGC-823 S180肉瘤 肝癌H22腹水瘤 抑瘤率 肿瘤移植 抗肿瘤活性 

分 类 号：R285.5[医药卫生—中药学]